scispace - formally typeset
D

Daniel J. Conklin

Researcher at University of Louisville

Publications -  141
Citations -  5476

Daniel J. Conklin is an academic researcher from University of Louisville. The author has contributed to research in topics: Acrolein & Medicine. The author has an hindex of 39, co-authored 126 publications receiving 4254 citations. Previous affiliations of Daniel J. Conklin include University of Texas Medical Branch & American Heart Association.

Papers
More filters
Journal ArticleDOI

Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation.

TL;DR: Episodic PM2.5 exposures are associated with increased endothelial cell apoptosis, an antiangiogenic plasma profile, and elevated levels of circulating monocytes and T, but not B, lymphocytes, which could contribute to the pathogenic sequelae of atherogenesis and acute coronary events.
Journal ArticleDOI

miR-301a as an NF-κB activator in pancreatic cancer cells.

TL;DR: It is demonstrated that miR‐301a down‐regulates NF‐κB‐repressing factor (Nkrf) and elevates NF‐σκB activation, which supports a positive feedback loop as a mechanism for persistent NF‐γB activation.
Journal ArticleDOI

Aldehyde Detection in Electronic Cigarette Aerosols.

TL;DR: The emission of these aldehydes from all e-cigarettes, especially higher levels of aldeHydes from the newer-generation e-cigarette devices, indicates the risk of using e- cigarettes.
Journal ArticleDOI

Exposure to Fine Particulate Air Pollution Causes Vascular Insulin Resistance by Inducing Pulmonary Oxidative Stress

TL;DR: Exposure to fine particulate air pollution causes vascular insulin resistance by inducing pulmonary oxidative stress and suppression of vascular insulin signaling by PM2.5 may accelerate the progression to systemic insulin resistance, particularly in the context of diet-induced obesity.
Journal ArticleDOI

Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.

TL;DR: PC 153 is an obesogen that exacerbates hepatic steatosis, alters adipocytokines and disrupts normal hepatic lipid metabolism when administered with HFD but not control diet, potentially impacts human obesity/NAFLD.